Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 15/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 8/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 3/20 | 1.00 |
| ▸ | EIF2AK1 | Q9BQI3 | 3/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 2/20 | 1.00 |
| ▸ | MAP3K10 | Q02779 | 2/20 | 1.00 |
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 2/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384284 | 1.00 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL30500616 | 1.00 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL868254 | 1.00 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL28589747 | 0.93 | EIF2AK3 (0.87) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL869189 | 0.90 | RIPK1 (0.82) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL869448 | 0.90 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL870488 | 0.90 | RIPK1 (0.81) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL869419 | 0.90 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL28814384 | 0.90 | EIF2AK3 (0.86) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL29433603 | 0.90 | EIF2AK3 (0.81) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118161473-A | ISRIB application in preparing medicine for preventing and treating ischemic cerebral apoplexy | 苏州大学 | 2024-06-11 | — | — | CN | claimed |
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2024-03-14 | — | — | US | claimed |
| EP-4255423-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | Lankenau Institute for Medical Research (US) | 2023-10-11 | — | — | EP | claimed |
| CN-116806149-A | Methods and compositions for treating pathological conditions involving neovascularization using IDO 1-dependent angiogenic cells | 兰肯瑙医学研究所 | 2023-09-26 | — | — | CN | claimed |
| WO-2022125553-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2022-06-16 | — | — | WO | claimed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | claimed |
| CN-114867527-B | Macrocyclic peptides | Herantis pharmaceutical Co. (FI) | 2026-05-26 | — | — | CN | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025024776-A2 | COMPOSITIONS COMPRISING XBP1 FRAGMENTS AND METHODS OF USE IN GENE THERAPY | DUKE UNIVERSITY (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20250025473-A1 | CELL IMPERMEABLE KINASE INHIBITORS TO TREAT SARS-COV-2 AND/OR HSV VIRAL INFECTIONS | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2025-01-23 | — | — | US | disclosed |
| CN-119285744-A | Reverse-reverse peptides | 赫兰提斯制药公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118680909-A | Application of xanthone in preparing PERK protein phosphorylation inhibitor and preparing neuroprotection and cognition improving drugs | 成都中医药大学 | 2024-09-24 | — | — | CN | disclosed |
| CN-114846020-B | Reverse-reverse peptides | 赫兰提斯制药公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-116761595-A | Eye drops for inhibiting myopia progression of children and screening method of myopia progression inhibitor for children | 坪田实验室股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20230158016-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| US-20230107770-A1 | METHOD OF ENHANCING IMMUNOTHERAPY USING ER STRESS PATHWAY INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4051286-A1 | METHODS AND COMPOSITIONS FOR TREATING UVEAL MELANOMA | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-07 | — | — | EP | disclosed |
| CN-112807434-B | Application of PERK inhibitor in preparation of synergist of liver cancer drug | 中山大学 | 2022-04-05 | — | — | CN | disclosed |
| CN-112402424-B | Small molecule medicine and application thereof in treating intermittent hypoxia | 杭州医学院 | 2022-03-29 | — | — | CN | disclosed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | IDO1, IDO2, TIE1 | EIF2AK3 3142/4885RIPK1 88/4885EIF2AK2 270/4885 |
| US-20230158016-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY | OPRD1, OPRM1, OPRK1 | EIF2AK3 1505/4885RIPK1 1600/4885EIF2AK2 457/4885 |
| US-20250025473-A1 | CELL IMPERMEABLE KINASE INHIBITORS TO TREAT SARS-COV-2 AND/OR HSV VIRAL INFECTIONS | PDPK1, DAPK1, DAPK2 | EIF2AK3 896/4885RIPK1 42/4885EIF2AK2 184/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | EIF2AK3 2073/4885RIPK1 160/4885EIF2AK2 1560/4885 |
| US-20230107770-A1 | METHOD OF ENHANCING IMMUNOTHERAPY USING ER STRESS PATHWAY INHIBITORS | DDIT3, NFATC1, MCL1 | EIF2AK3 70/4885RIPK1 435/4885EIF2AK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.